Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024)

Neurocrine Biosciences' Short term Debt history spans 6 years, with the latest figure at $122.8 million for Q1 2024.

  • For Q1 2024, Short term Debt changed N/A year-over-year to $122.8 million; the TTM value through Mar 2024 reached $122.8 million, changed N/A, while the annual FY2023 figure was $170.1 million, 0.41% changed from the prior year.
  • Short term Debt reached $122.8 million in Q1 2024 per NBIX's latest filing, down from $170.1 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $425.0 million in Q3 2020 to a low of $122.8 million in Q1 2024.
  • Average Short term Debt over 4 years is $227.0 million, with a median of $169.8 million recorded in 2023.
  • The largest YoY upside for Short term Debt was 0.41% in 2023 against a maximum downside of 0.41% in 2023.
  • A 4-year view of Short term Debt shows it stood at $425.0 million in 2020, then crashed by 60.14% to $169.4 million in 2022, then increased by 0.41% to $170.1 million in 2023, then dropped by 27.81% to $122.8 million in 2024.
  • Per Business Quant, the three most recent readings for NBIX's Short term Debt are $122.8 million (Q1 2024), $170.1 million (Q4 2023), and $169.9 million (Q3 2023).